Stock Code: 688506 Stock Abbreviation: Baili Tianheng Announcement No.: 2026-060

Sichuan Baili Pharmaceutical Co., Ltd.

Voluntary Disclosure Announcement Regarding the Interim Analysis of the Phase III Clinical Trial of Lonkatuzumab Vedotin/Iza-bren (BL-B01D1/iza-bren) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Reaching Its Primary Endpoint

The Company's Board of Directors and all directors warrant that this announcement contains no false records, misleading statements, or material omissions, and assume individual and joint legal liability for the truthfulness, accuracy, and completeness of its content.

Sichuan Baili Pharmaceutical Co., Ltd. (the “Company”) has independently developed the world's first-in-class, new-concept, and the world's first and only approved and marketed EGFR×HER3 bispecific antibody-drug conjugate (ADC), Lonkatuzumab Vedotin/Iza-bren (BL-B01D1/iza-bren). In its Phase III clinical trial in non-small cell lung cancer (study protocol number: BL-B01D1-301), the Independent Data Monitoring Committee (iDMC) determined that the pre-specified interim analysis met the primary endpoint of progression-free survival (PFS), with a trend toward benefit also observed in overall survival (OS). The indication is: locally advanced or metastatic non-small cell lung cancer with EGFR-sensitizing mutations that has progressed following prior EGFR-TKI therapy. This marks the fourth Phase III clinical study in which this bispecific ADC has met its primary endpoint, and the first Phase III clinical study worldwide in which a bispecific ADC drug has met its primary endpoint in the treatment of non-small cell lung cancer.

I. Basic Information about the Drug

Lonkatuzumab Vedotin/Iza-bren (BL-B01D1/iza-bren) is the world's first-in-class, new-concept, and the world's first and only approved and marketed EGFR×HER3 bispecific antibody-drug conjugate (ADC). Lonkatuzumab Vedotin has received marketing approval from the National Medical Products Administration (NMPA) for two indications: relapsed or metastatic nasopharyngeal carcinoma and relapsed or metastatic esophageal squamous cell carcinoma. In addition, its New Drug Application (NDA) for the treatment of locally advanced or metastatic triple-negative breast cancer has also been accepted for review by the Center for Drug Evaluation (CDE).

As of now, Lonkatuzumab Vedotin has initiated more than 40 clinical trials in China and the United States covering multiple tumor types, including 20 Phase III clinical studies (including Phase II/III studies). Seven indications for Lonkatuzumab Vedotin have been included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, two indications have been included in the Priority Review list by the CDE, and one indication has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA).

II. Risk Warning

In accordance with the laws and regulations relating to drug registration in China, drugs must complete the relevant clinical trials and be reviewed and approved by the National Medical Products Administration before they may be marketed and sold.

Given the high-technology, high-risk, and high-value-added characteristics of pharmaceutical products, the process from clinical trial approval to production involves a long cycle with many stages and is susceptible to uncertain factors. The Company will actively advance the above research and development project in accordance with relevant regulations, and will strictly fulfill its information disclosure obligations regarding subsequent progress of the project in a timely manner in accordance with relevant regulations. Investors are advised to make prudent decisions and to be mindful of investment risks.

This announcement is hereby made.

Board of Directors

Sichuan Baili Pharmaceutical Co., Ltd.

August 18, 2026